Evaluations of Biomarkers Associated with 5-FU Sensitivity for Non-small-cell Lung Cancer Patients Postoperatively Treated with UFT
Overview
Affiliations
The sensitivity to 5-fluorouracil (5-FU) has been reported to be associated with target molecule thymidylate synthase (TS), fluoropyrimidine-metabolising enzymes such as orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD). We performed an immunohistochemical study on the clinical significance of TS, OPRT, and DPD expression using 151 resected non-small-cell lung cancer (NSCLC) patients postoperatively treated with a combination of tegafur and uracil (UFT). Eighty-two carcinomas were TS-positive, 105 carcinomas were OPRT-positive, 68 carcinomas were DPD-positive. No correlation was observed in the HSCORE between the TS and OPRT expression (r=0.203), between the TS and DPD expression (r=0.098), or between the OPRT and DPD expression (r=0.074). Regarding the survival of NSCLC patients treated with UFT, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that with TS-positive tumours (P=0.0133). The 5-year survival rate of patients with OPRT-positive stage II to III tumours was significantly higher than that with OPRT-negative stage II to III tumours (P=0.0145). In addition, the 5-year survival rate of patients with DPD-negative tumours was also significantly higher than that with DPD-positive tumours (P=0.0004). A Cox multivariate regression analysis revealed the TS status (hazard ratio 2.663; P=0.0003), OPRT status (hazard ratio 2.543; P=0.0005), and DPD status (hazard ratio 2.840; P<0.0001) to all be significant prognostic factors for the survival of resected NSCLC patients postoperatively treated with UFT.
5FU encapsulated polyglycerol sebacate nanoparticles as anti-cancer drug carriers.
Sivanesan D, Verma R, Prasad E RSC Adv. 2022; 11(31):18984-18993.
PMID: 35478658 PMC: 9033480. DOI: 10.1039/d1ra01722e.
Sakon K, Sasaki M, Tanaka K, Mizunaga T, Yano K, Kawamura Y Discov Oncol. 2022; 12(1):19.
PMID: 35201464 PMC: 8777502. DOI: 10.1007/s12672-021-00413-w.
Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma.
Kaira K, Imai H, Yamaguchi O, Mouri A, Kagamu H Cancers (Basel). 2021; 13(21).
PMID: 34771601 PMC: 8582353. DOI: 10.3390/cancers13215441.
Imai H, Shimizu K, Kawashima O, Endoh H, Imaizumi K, Goto Y Cancers (Basel). 2019; 11(11).
PMID: 31653009 PMC: 6895922. DOI: 10.3390/cancers11111636.
Himuro N, Niiya Y, Minakata T, Oshima Y, Kataoka D, Yamamoto S Mol Clin Oncol. 2018; 9(6):640-646.
PMID: 30546894 PMC: 6256090. DOI: 10.3892/mco.2018.1726.